Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Total Current Liabilities (2023 - 2025)

Beta Bionics' Total Current Liabilities history spans 3 years, with the latest figure at $30.9 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 46.23% year-over-year to $30.9 million; the TTM value through Dec 2025 reached $30.9 million, up 46.23%, while the annual FY2025 figure was $30.9 million, 46.23% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $30.9 million at Beta Bionics, up from $25.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $30.9 million in Q4 2025 and bottomed at $10.6 million in Q4 2023.
  • The 3-year median for Total Current Liabilities is $20.3 million (2024), against an average of $20.7 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 99.42% in 2024 before it soared 46.23% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $10.6 million in 2023, then surged by 99.42% to $21.1 million in 2024, then skyrocketed by 46.23% to $30.9 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Total Current Liabilities are $30.9 million (Q4 2025), $25.4 million (Q3 2025), and $19.5 million (Q2 2025).